Viking Therapeutics is a company that makes medicine to help people with health problems related to their metabolism and hormones. They have some products in development, which are drugs that can treat different conditions. The stock price of the company has gone up a little bit recently, but some experts think it might be too high. They also expect to report how well they are doing with their business soon. Some people who know a lot about the company and its products have given their opinions on what the stock price should be, and most of them think it will go higher in the future. Read from source...

- The title of the article is misleading and sensationalized. It implies that whales are somehow involved in trading VKTX stock, which is not true. Whales are just a metaphor for large investors who can influence the market price, but they do not directly represent any marine mammals or aquatic life forms.
- The article does not provide any evidence or data to support its claims about Viking Therapeutics' products, clinical trials, or business performance. It relies on vague statements like "check out what whales are doing" and "Viking Therapeutics is a healthcare service provider", without explaining what that means or how it relates to the stock price or the company's future prospects.
- The article does not mention any of the risks or challenges that Viking Therapeutics faces, such as competition from other biopharmaceutical companies, regulatory hurdles, funding requirements, clinical trial results, or market demand for its products. It also does not address any of the potential benefits or advantages that Viking Therapeutics might have over its competitors, such as innovation, patents, partnerships, or expertise.
- The article uses vague and subjective terms like "approaching overbought", "over the past month", "average target price", and "in a cautious move", without defining what they mean or how they are derived. It also does not provide any context or comparison for these terms, such as historical trends, market volatility, sector performance, or industry standards.
- The article ends with a promotion for Benzinga's services and products, which is irrelevant to the topic of Viking Therapeutics and its stock price. It also does not disclose any conflicts of interest that Benzinga might have in writing or publishing this article, such as ownership, compensation, affiliation, or endorsement.

VKTX is a biopharmaceutical company that develops treatments for metabolic and endocrine disorders. It has a strong pipeline of products, including VK2809, VK5211, and VK0214. The stock price has been rising recently, but the RSI indicator suggests it may be approaching overbought territory. There are mixed opinions among professional analysts, with some expecting a higher target price of $90.0, while others are more cautious.